Lightlake Therapeutics, Inc Appoints Mary K Pendergast as Regulatory and Strategy Advisor
29 Dezember 2010 - 3:15PM
Lightlake Therapeutics Inc (OTCBB:LLTP) is pleased to announce that
it has appointed Mary K. Pendergast J.D., LL.M., as its advisor for
Regulatory and Strategic Matters.
Mary Pendergast is President of Pendergast Consulting, a legal
and regulatory consulting firm founded in 2003. Her background
consists of a distinguished pedigree in her field including serving
as Deputy Commissioner and Senior Advisor at the U.S. Food and Drug
Administration.
While at the FDA, Ms. Pendergast also served as Associate Chief
Counsel for Enforcement and as Attorney, Office of the General
Counsel, Dept. of Health and Human Services. She was
responsible for FDA efforts to regulate emerging technologies such
as cellular and tissue-based therapies, biotechnology, genetic
testing, xeno-transplantation and acute-care research.
"We are honored to have added Ms. Pendergast to our team,"
states Lightlake Therapeutics CEO, Dr. Roger Crystal, "She has
exceptional experience and expertise, that will help Lightlake
navigate through the increasingly challenging regulatory
landscape."
Chairman Dr Michael Sinclair added: "Mary's previous work with
the FDA and in biotech will be invaluable for Lightlake, as we look
to expand our portfolio into other areas, such as using opioid
antagonists for the treatment of methadone dependency."
"I am very excited to be joining such an interesting venture.
Lightlake's approach really differentiates itself and has the real
potential to deliver where others have failed. Using single agents
that are well known for their safety and effectiveness in related
areas is very promising" commented Mary Pendergast.
Mary Pendergast received her LL.M., J.D., and B.A. degrees from
Yale Law School, the University of Iowa College of Law, and
Northwestern University, respectively.
About Lightlake Therapeutics
Lightlake Therapeutics is an early stage biopharmaceutical
company aiming to build a solid platform of pharmacological
treatments based on our expertise using opioid antagonists.
Significant developments include the use of an opioid antagonist
nasal spray to address binge-eating obesity. A Phase II trial of
this product in Helsinki is due to be completed during
2011.
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
CONTACT: Lightlake Therapeutics Inc
Dr Roger Crystal, CEO
roger.crystal@lightlake.fi
Dr Michael Sinclair, Chairman
michael.sinclair@lightlake.fi
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024